V. Korman

发表

Mechanism and Efficacy of Sub–50-nm Tenfibgen Nanocapsules for Cancer Cell–Directed Delivery of Anti-CK2 RNAi to Primary and Metastatic Squamous Cell Carcinoma

T. Kimbrough, F. Ondrey, R. Vogel, 2014, Molecular Cancer Therapeutics.

CK2 Modulation of NF-κB, TP53, and the Malignant Phenotype in Head and Neck Cancer by Anti-CK2 Oligonucleotides In vitro or In vivo via Sub–50-nm Nanocapsules

C. Van Waes, Zhong Chen, Hai Lu, 2010, Clinical Cancer Research.

Troponin-Tropomyosin Control of Thin Filament Activity Revealed by Electron Microscopy and 3-D Reconstruction.

J. V. Van Eyk, W. Lehman, V. Korman, 2000, Microscopy and Microanalysis.

Mutations in Actin Subdomain 3 That Impair Thin Filament Regulation by Troponin and Tropomyosin*

V. Korman, L. Tobacman, 1999, The Journal of Biological Chemistry.

Tenfibgen-DMAT Nanocapsule Delivers CK2 Inhibitor DMAT to Prostate Cancer Xenograft Tumors Causing Inhibition of Cell Proliferation.

G. Niehans, R. Vogel, G. Unger, 2014, Molecular and cellular pharmacology.

Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice.

C. Steer, G. Unger, B. Kren, 2009, The Journal of clinical investigation.

CK2 targeted RNAi therapeutic delivered via malignant cell-directed tenfibgen nanocapsule: dose and molecular mechanisms of response in xenograft prostate tumors

G. Niehans, R. Vogel, G. Unger, 2016, Oncotarget.

Structural dynamics of the actin-myosin interface by site-directed spectroscopy.

M. Titus, David D. Thomas, V. Korman, 2006, Journal of molecular biology.

Site-directed spectroscopic probes of actomyosin structural dynamics.

David D. Thomas, V. Korman, D. Kast, 2009, Annual review of biophysics.

Tropomyosin and actin isoforms modulate the localization of tropomyosin strands on actin filaments.

R Craig, W Lehman, J. V. Van Eyk, 2000, Journal of molecular biology.

Systemic administration of antisense oligonucleotides simultaneously targeting CK2α and α′ subunits reduces orthotopic xenograft prostate tumors in mice

G. Unger, B. Kren, V. Korman, 2011, Molecular and Cellular Biochemistry.

Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells.

L. Pinna, G. Unger, B. Kren, 2012, Cancer letters.

Tenfibgen Ligand Nanoencapsulation Delivers Bi-Functional Anti-CK2 RNAi Oligomer to Key Sites for Prostate Cancer Targeting Using Human Xenograft Tumors in Mice

R. Vogel, G. Unger, B. Kren, 2014, PloS one.

An Actin Subdomain 2 Mutation That Impairs Thin Filament Regulation by Troponin and Tropomyosin*

W. Lehman, V. Korman, R. Craig, 2000, The Journal of Biological Chemistry.